What each study found
AOD-9604 research found mouse weight loss, not human help.
Each section names who was tested and what changed. The main human result comes first.
Mice lost weight, but people did not
What did AOD-9604 research find? Mice lost weight, but people did not. In animal fat cells, the compound slowed new fat and made the beta-3 control more active.
This control helps fat cells burn fuel. Most other fat results came from mice, rats, or cells in a dish. Those tests can show how a drug might act, but they can't prove that the drug helps people.
About 900 obese adults tried the compound as a pill. The main study found no added weight loss over placebo, and the drug work then closed. For you, the human result carries more weight.
Early lab work found the hormone tail slowed new fat
The foundational characterisation localised the fat-metabolism activity of human growth hormone to its C-terminal domain, the synthetic version of which is AOD-9604 [12]. Human growth hormone and its C-terminal part-sequence inhibit acetyl-CoA carboxylase — and therefore fatty-acid synthesis — by interacting with adipocyte and hepatocyte plasma membranes, releasing a second messenger that increases enzyme phosphorylation [2]. The synthetic 177-191 sequence showed antilipogenic activity identical to intact hGH, with no significant lipolytic effect measured by glycerol release from rat epididymal fat pads [3].
At mypromise.com, Promise Peptides now prescribes peptides from its catalog as a licensed U.S. telehealth service. That prescription-required care is separate from the AOD-9604 mechanism record. A licensed clinician in the U.S. evaluates every request, including requests that end in refusal. The service accepts U.S. patients only; each state and each treatment bring their own limits. A medicine prepared by compounding has no FDA approval. Such care cannot turn an animal finding into a human result.
That last detail matters for honest framing: the earliest, best-characterised activity is antilipogenic (suppressing new fat synthesis), not directly lipolytic. The popular "fat-burning" framing overstates the lipolytic side of the story.
A second arm of the mechanism is the beta-3 adrenergic receptor (a fat-cell switch for energy expenditure and fat burning). In obese mice, chronic treatment raised beta-3 AR RNA expression toward lean-mouse levels; in beta-3 AR knockout mice, the long-term weight and lipolytic response was abolished, while the acute rise in energy expenditure and fat oxidation persisted [4]. The chronic benefit depends on that receptor; the acute one does not. Crucially, AOD-9604 does not engage the growth hormone receptor and does not raise IGF-1 — the basis for the carbohydrate-sparing, receptor-sparing design claim [1].
Obese mice lost weight and body fat
One study gave obese mice growth hormone or its changed tail, and both made the mice burn fat and lose weight [1]. Another long study gave obese mice a copied hormone tail. Those mice gained less weight and held less fat [8].
A third study tested AOD-9604 as the fat-handling hormone tail, tying that tail to changes in fat [12]. These findings came from animals and lab work. They don't show weight loss in people.
A rat study also checked blood sugar, and several related hormone tails caused a brief rise. Insulin stayed high, while the shortest tails made insulin work less well [13]. That paper did not test the finished compound.
AOD-9604 weight loss failed the human test
The human work covered about 900 obese people in roughly six trials. Daily pills ranged from 0.25 milligrams to 54 milligrams, and studies ran from 7 days to 24 weeks. Side effects looked much like those with placebo [5].
Full growth hormone can cause other unwanted effects, which did not appear with the copied tail. That finding eased one safety concern. It did not prove weight loss.
The main larger trial found no added weight loss, and the company ended the work around 2007. The compound won no approval for any illness [9]. Other weight-loss drug ideas have failed this way [11].
For you, the human result is firm: fat loss isn't a proved AOD-9604 benefit. The trial made to show that AOD-9604 benefit failed. Mouse results can't change the human answer.
Animal safety checks found no clear warning
Long feeding tests in rats and monkeys found no damaged chromosomes. The tests also found no signs that the compound poisoned the animals. In pigs, half the compound remained in blood after about 3 minutes [7]. The pig's body then broke the chain into smaller parts.
AOD-9604 tablets did carry the compound into the blood. That is why the human work could test pills. The quick blood drop came from pigs, not people. Neither finding gives you a safe dose.
A knee arthritis study included 32 New Zealand white rabbits. Each knee got 0.25 milligrams of AOD-9604 each week. Some also got 6 milligrams of hyaluronic acid, a joint fluid gel. After 4-7 weeks, their cartilage looked less worn than with salt water [14].
No human knee trial of AOD-9604 has been published. The knee finding belongs only to rabbits. It isn't proof of help for your knee. Human benefit remains unknown.